Diabetes Center is thrilled to announce the appointment of Zoe Quant MD, who shares this with the Department of Endocrinology, where she cares for patients who develop hormonal side effects from their cancer treatment, especially from immunotherapy, working with them to continue critical cancer treatments while optimizing their quality of life. She is the clinical lead for adults eligible for teplizumab, an immunotherapy approved to delay the onset of type 1 diabetes.
Quandt's research mirrors her work with patients. Her research goals include predicting who will develop endocrine side effects (such as thyroid dysfunction, pituitary disfunction and diabetes) from cancer therapy, understanding why these side effects happen, and determining what they mean for the cancer treatment as well as what can be done to address them. She also studies how these immune-triggered side effects relate to spontaneous autoimmune endocrine disease. This research, which guides her patient care on a daily basis, has received funding from the National Institutes of Health, American Diabetes Association, Larry L. Hillblom Foundation and Parker Institute for Cancer Immunotherapy. Additionally, she is one of the leaders of the UCSF Endocrine Clinical and Translational Research Center.
Quandt earned her medical degree at UCSF. She completed a residency in internal medicine at Stanford Medicine, followed by a fellowship in diabetes, endocrinology and metabolism at UCSF in Mark Anderson's lab.
In her free time, Quandt is often chasing after her two young kids and small dog in a variety of outdoor settings. She is a lover of database creation, particularly for making restaurant reservations while vacation planning.